CORPORATE FINANCIALS ONLINE Fastest direct links to news from publicly-traded companies.

             Competitive Tech: Erectile Dsyfunction Drug Development


For Immediate Release

                                 


  CTT Licensee Palatin Technologies To Begin Clinical Development
                                 
                Of PT-141 Erectile Dysfunction Drug
                                 
                                 
Fairfield, CT - (June 26, 2000) - Competitive Technologies, Inc.
(AMEX:CTT) today confirmed that its licensee, Palatin Technologies, Inc.
(AMEX:PTN), plans to begin the clinical development of its erectile
dysfunction drug, PT-141, which will be administered as a nasal spray.

Revenues generated from any FDA approved Palatin products using CTT
technologies will produce royalties for CTT and its client, the
University of Arizona.

Palatin reported that in a June 20 meeting with the U.S. Food and Drug
Administration (FDA), they reviewed the preclinical safety data on
PT-141 and reached agreement on the design of initial clinical trials.
Palatin anticipates filing an Investigational New Drug (IND) application
later this summer. The initial study will evaluate safety,
pharmacokinetics and efficacy in 32 men with erectile dysfunction.

According to Carl Spana, Ph.D., Palatin Technologies' President and CEO,
"The pre-clinical data indicate that PT-141 has the potential to be free
of the cardiac side effects found in many of today's  treatments for
erectile dysfunction.  It works by stimulating receptors in the central
nervous system and has proven to be highly potent in animal studies in
several species. We look forward to starting clinical trials later this
year."

Competitive Technologies has exclusively licensed the technology
underlying  PT-141 to Palatin.  Palatin is a development-stage medical
technology company developing and commercializing pharmaceutical
products for diagnostic imaging and therapy based on its proprietary
monoclonal antibody radiolabeling and enabling peptide platform
technologies.  (Web site:  www.palatin.com)

About Competitive Technologies, Inc.

Competitive Technologies is a global leader in identifying, developing
and commercializing innovative life sciences, physical sciences and
digital  technologies.   Competitive Technologies' specialized expertise
and experience make it a valuable partner for inventors, companies and
universities of all sizes.  CTT has been responsible for closing
hundreds of licensing  agreements. CTT clients include:  Lucent
Technologies,  Matsushita Electric Industrial,  NTRU Cryptosystems,
Palatin Technologies,  Inc.  and Ribozyme Pharmaceuticals, Inc.
Competitive Technologies, Inc.  is based in Fairfield, Connecticut and
has affiliates in Osaka, Japan and London, England.

Statements about the Company's future expectations, including
development and regulatory plans, and all other statements in this
document other than historical facts are "forward-looking statements"
within the meaning of applicable Federal Securities Laws and are not
guarantees of future performance.  These statements involve risks and
uncertainties related to market acceptance of and competition for the
Company's licensed technologies and other risks and uncertainties
inherent in CTT's business, including those set forth in Item 1 of the
Company's Form  10-K for the year ended July 31, 1999 and other factors
that may be described in CTT's filings with the SEC, and are subject to
change at any time. The Company's actual results could differ materially
from these forward-looking statements.  The Company undertakes no
obligation to update publicly any forward-looking statement.


Direct inquiries to:

Johnnie D. Johnson
Strategic IR, Inc.
800 Third Avenue
Suite 3700
New York, NY  10022
Tel. (212) 754-6565
Fax (212) 754-4333
E-mail: jdjohnson@strategic-ir.com

E-mail: ctt@competitivetech.net
Web site: http://www.competitivetech.net




End